Decide at what price you'd be comfortable buying and we'll help you stay ready.
Celanese combines cyclical chemical pricing and volume exposure with operating margins that have varied substantially across demand and cost cycles. It has generally generated free cash flow with comparatively modest capital spending, while its debt-heavy balance sheet makes sustained cash generation important for deleveraging.
Third-quarter sales increased year over year but eased from the prior quarter, while the quarterly cash-flow rebound benefited from a working-capital inflow. Trailing free cash flow remains below the year-earlier level, so the latest quarter does not yet establish a durable change in cash generation.
Whether trailing operating cash flow and free cash flow stabilize as the favorable quarterly working-capital contribution rolls through.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 906m | 849m | 1.2B | 858m | 2B | 1.9B | 1.9B | 2B | (1.5B) | (1.2B) | |
| 295m | 310m | 349m | 356m | 356m | 378m | 478m | 739m | 823m | 786m | |
| 83m | (152m) | 137m | (31m) | 77m | 13m | (835m) | (967m) | 216m | (278m) | |
| 31m | 47m | 71m | 48m | 28m | 95m | 60m | 40m | 32m | 24m | |
| (273m) | (377m) | 107m | 120m | (1.4B) | (42m) | (6m) | (353m) | 1.6B | 1.6B | |
| 129m | 123m | 100m | 157m | 167m | 215m | 273m | 237m | 349m | 255m | |
| 130m | 130m | 133m | 118m | 120m | 105m | 122m | 780m | 701m | 671m | |
| (118m) | 173m | (248m) | 151m | 280m | (488m) | 280m | 516m | (204m) | 235m | |
| 893m | 803m | 1.6B | 1.5B | 1.3B | 1.8B | 1.8B | 1.9B | 966m | 1.1B | |
| (246m) | (267m) | (337m) | (370m) | (364m) | (467m) | (543m) | (568m) | (435m) | (343m) | |
| (193m) | (282m) | (170m) | (123m) | 956m | (652m) | (10.6B) | 434m | (35m) | (6m) | |
| (439m) | (549m) | (507m) | (493m) | 592m | (1.1B) | (11.1B) | (134m) | (470m) | (349m) | |
| (494m) | (499m) | (805m) | (997m) | (650m) | (1B) | (17m) | 0 | 1m | — | |
| (7m) | 443m | (40m) | 412m | (472m) | 404m | 10.8B | (1.1B) | (948m) | (323m) | |
| (201m) | (241m) | (280m) | (300m) | (293m) | (304m) | (297m) | (305m) | (307m) | (13m) | |
| (57m) | (54m) | (40m) | (50m) | (56m) | (142m) | (175m) | (63m) | (59m) | (177m) | |
| (759m) | (351m) | (1.2B) | (935m) | (1.5B) | (1B) | 10.3B | (1.5B) | (1.3B) | (513m) | |
| (24m) | 35m | (23m) | (2m) | 28m | (15m) | 4m | (12m) | (26m) | 17m | |
| (329m) | (62m) | (137m) | 24m | 492m | (419m) | 972m | 297m | (843m) | 301m | |
| 647m | 536m | 1.2B | 1.1B | 979m | 1.3B | 1.3B | 1.3B | 531m | 803m |
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more
